Innovative Medicines based on ImmunoModulatory Biologics
About IMBiologics
Research and Development of Antibody Therapeutics
We focus on protecting human health by bringing back homeostasis, a physiological balance of a healthy person, through developing novel innovative immunomodulatory antibody drugs.
We are accelerating the development of innovative immunomodulatory antibody therapeutics to treat autoimmune diseases and cancer with our own platform technology and in-licensed drug candidates.
By Sungmin Kim, Biospectator | Published: October 14, 2025, 08:44 KST | Updated: October 14, 2025, 08:44 KST
IMBiologics, which is developing pipelines for autoimmune diseases and immuno-oncology therapeutics, has been accelerating its R&D efforts. Since its establishment in 2020, the company has raised a total of 79.2 billion KRW in cumulative funding. In August, it passed the technology evaluation required for a special listing on KOSDAQ.
▲Kyong-sik Ha, CEO of IMBiologics
IMBiologics announced on the 14th that it has successfully closed a pre-IPO funding round worth 42.2 billion KRW. With this latest round, the total funds raised by the company since its founding in August 2020 now amount to 79.2 billion KRW. Previously, the company secured 4 billion KRW in seed funding in 2021, followed by 13 billion KRW in Series A, and 20 billion KRW in Series B funding in 2023.
In August of this year, IMBiologics passed the technology evaluation for a special KOSDAQ listing and is targeting an IPO in the first half of next year.
Participating follow-on investors in this round include Atinum Investment, Partners Investment, CJ Investment, K2 Investment Partners, Prodigy Investment, Shinhan Venture Investment, Wooshin Venture Investment, Timefolio Capital/Shinhan Capital, LSK Investment, and Kingo Investment Partners. New investors include Korea Development Bank (KDB), Quad Asset Management, DS Asset Management/DS Investment Partners, AJU IB, Korea Investment & Securities, and Shinhan Investment Corp.
IMBiologics plans to use the newly secured funds to develop new drug programs for autoimmune diseases and immuno-oncology therapies, and to form global partnerships. In August, the company entered into a joint development partnership with Chinese biotech firm GeneQuantum for multivalent antibody-drug conjugates (ADCs). This collaboration combines IMBiologics\' multivalent antibody backbone platform technology, ePENDY (enhanced/engineered PENtamer boDY), with GeneQuantum’s payload and linker technologies.
CEO Kyung-sik Ha of IMBiologics stated, “In addition to the pipelines that have already been licensed out, we plan to expand our core pipeline currently under research, accelerate development, and deliver new business results. We are committed to growing into a global biotech company that launches innovative new drugs in the fields of autoimmune disease and immuno-oncology.”
자가면역질환 및 면역항암제 파이프라인 개발 속도..2020년 설립후 누적 투자금 총 792억..지난 8월 코스닥 기술성평가 통과
▲하경식 아이엠바이오로직스 대표
아이엠바이오로직스(IMBiologics)는 pre-IPO 라운드로 422억원 규모의 투자유치를 마무리했다고 14일 밝혔다. 이로써 아이엠바이오로직스는 지난 2020년 8월 설립된 이후 누적 투자금으로 총 792억원을 펀딩하게 됐다. 앞서 2021년 시드투자 40억원 및 시리즈A로 130억원, 2023년 시리즈B로 200억원을 유치한 바 있다.
아이엠바이오로직스는 지난 8월 코스닥 기술특례상장을 위한 기술성 평가를 통과했으며, 내년 상반기중 코스닥 상장을 목표로 하고 있다.
이번 라운드에는 기존 투자자로 에이티넘인베스트먼트, 파트너스인베스트먼트, CJ인베스트먼트, 케이투인베스트먼트파트너스, 프로디지인베스트먼트, 신한벤처투자, 우신벤처투자, 타임폴리오캐피탈/신한캐피탈, LSK인베스트먼트, 킹고투자파트너스 등이 후속투자로 참여했다. 신규 투자자로는 한국산업은행, 쿼드자산운용, DS자산운용/DS투자파트너스, 아주IB, 한국투자증권, 신한투자증권 등이 참여했다.
아이엠바이오로직스는 이번에 확보한 투자금을 자가면역질환, 면역항암제 신약 프로그램의 개발과 글로벌 기업과 파트너십 등에 투입할 예정이다. 아이엠바이오로직스는 지난 8월 중국 바이오텍 진퀀텀(GeneQuantum)과 다중결합(multivalent) 항체-약물접합체(ADC) 공동개발 파트너십을 체결한 바 있다. 아이엠바이오로직스의 다중결합 항체 백본기술 ‘ePENDY(enhanced/engineered PENtamer boDY)’ 플랫폼 기술을 진퀀텀의 페이로드(payload), 링커 기술에 접목하는 내용이다.
하경식 아이엠바이오로직스 대표는 “기술이전(L/O)된 파이프라인 외에도, 현재 연구하고 있는 핵심 파이프라인을 확대하고, 개발을 가속화해 새로운 비즈니스 성과를 내겠다”며 “나아가 자가면역질환과 면역항암제 분야에서 혁신 신약을 출시하는 글로벌 바이오텍으로 성장하도록 노력을 집중하겠다”고 말했다.
Published: August 22, 2025, 09:20 | Updated: August 22, 2025, 09:34 By Sungmin Kim, BioSpectator
Applying GeneQuantum’s linker-payload technology to the multivalent antibody ‘ePENDY’… “Advantages
for proteins with low target expression and rapid internalization compared to IgG”
IMBiologics announced on the 22nd that it has signed a joint research agreement with Chinese biotech company GeneQuantum for the co-development of antibody-drug conjugates (ADCs).
IMBiologics is developing autoimmune disease therapies and immuno-oncology treatments based on its proprietary multivalent antibody backbone technology platform called ‘ePENDY (enhanced/engineered PENtamer boDY)’
Under this agreement, IMBiologics will jointly develop a new modality of multivalent antibody-based ADCs by combining GeneQuantum’s linker and payload technologies.
IMBiologics will identify and produce promising ADC targets using the ePENDY platform, while GeneQuantum will apply its linker and payload technologies to create ‘ePENDY ADC’ molecules and conduct characterization and efficacy evaluations. Specific ADC targets and contract terms were not disclosed.
IMBiologics’ ePENDY technology, unlike IgG antibodies that have two antigen-binding variable domains, is based on an IgM structure and can bind to up to 10 target proteins. This results in high overall avidity for antigens and creates a clustering effect, making it suitable for agonistic properties that activate immune cells.
Recently, IMBiologics discovered that the ePENDY technology demonstrates higher efficacy than IgG antibodies for proteins with low target expression or at low effective doses, and it internalizes into cells faster than IgG antibodies after binding to target proteins. Based on these characteristics, the company expects that ADCs using ePENDY can overcome the limitations of existing IgG-based ADCs.
IMBiologics CEO Ha Kyung-sik expressed his satisfaction with the collaboration with GeneQuantum, emphasizing that this joint research marks an important global partnership that leverages the advantages of ePENDY over IgG antibodies. He noted that the project holds significant meaning in terms of the completeness and scalability of the platform technology, and added that the company will continue to pursue various collaborations and business achievements with global partners using the ePENDY platform.
GeneQuantum CEO Qin Gang stated that the partnership represents an important opportunity to expand and globalize the company’s proprietary enzymatic conjugation technology. He expressed expectations that combining this technology with IMBiologics’ next-generation ePENDY platform will enable the development of next-generation ADCs that target a broader range of cancers, overcome tumor heterogeneity and drug resistance, and achieve an improved therapeutic window.
![\"아이엠바이오,](\"https://img.etoday.co.kr/pto_db/2025/10/20251014083736_2237798_560_432.png\")
![\"아이엠바이오,](\"https://img.etoday.co.kr/pto_db/2025/08/20250822085952_2215202_446_317.png\")
